[{"data":1,"prerenderedAt":274},["ShallowReactive",2],{"drug-dasatinib":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":67,"contraindications":138,"warnings":139,"renal":147,"monitoring":148,"interactions":149,"review":150,"examples":153,"atc":172,"iran":174,"usApproval":209,"links":215,"populations":231},"dasatinib",1,{"fa":7,"en":8},"داساتینیب","Dasatinib","antineoplastic-immunomodulating",{"fa":11,"en":12},"مهارکننده تیروزین کیناز BCR-ABL","BCR-ABL tyrosine kinase inhibitor",[14],{"name":15,"market":16},"Sprycel","US",[18,19,7],"sprycel","اسپرایسل",[21,35,43,51,59],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-20","tablet","oral","20 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},20,"mg",false,[16],[32],{"source":33,"section":34},"fda-sprycel","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-50","50 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},50,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"tab-70","70 mg tablet",{"amount":47,"unit":28,"perUnit":23,"scored":29},70,[16],[50],{"source":33,"section":34},{"id":52,"form":23,"route":24,"label":53,"concentration":54,"markets":56,"refs":57},"tab-100","100 mg tablet",{"amount":55,"unit":28,"perUnit":23,"scored":29},100,[16],[58],{"source":33,"section":34},{"id":60,"form":23,"route":24,"label":61,"concentration":62,"markets":64,"refs":65},"tab-140","140 mg tablet",{"amount":63,"unit":28,"perUnit":23,"scored":29},140,[16],[66],{"source":33,"section":34},[68,90,105],{"id":69,"disease":70,"label":71,"population":74,"type":78,"unit":28,"dose":79,"refs":80,"notes":83},"cp","chronic-myeloid-leukemia",{"fa":72,"en":73},"CML فاز مزمن بزرگسال — ۱۰۰ mg یک بار در روز","Chronic-phase CML, adults — 100 mg once daily",{"minAge":75},{"value":76,"unit":77},18,"year","fixed",{"perDose":55,"dosesPerDay":5},[81],{"source":33,"section":82},"2.1",[84],{"text":85,"refs":88},{"fa":86,"en":87},"فقط زیر نظر متخصص انکولوژی؛ ادامه تا پیشرفت بیماری یا سمیت غیرقابل‌قبول. تنظیم دوز برای عوارض و تداخل‌ها طبق برچسب.","Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label.",[89],{"source":33,"section":82},{"id":91,"disease":70,"label":92,"population":95,"type":78,"unit":28,"dose":97,"refs":98,"notes":100},"adv",{"fa":93,"en":94},"CML فاز تسریع‌شده یا بلاست، یا ALL فیلادلفیا مثبت بزرگسال — ۱۴۰ mg یک بار در روز","Accelerated or blast-phase CML, or Ph+ ALL, adults — 140 mg once daily",{"minAge":96},{"value":76,"unit":77},{"perDose":63,"dosesPerDay":5},[99],{"source":33,"section":82},[101],{"text":102,"refs":103},{"fa":86,"en":87},[104],{"source":33,"section":82},{"id":106,"disease":70,"label":107,"population":110,"type":113,"unit":28,"dose":114,"refs":127,"notes":130},"child",{"fa":108,"en":109},"CML فاز مزمن یا ALL Ph+ کودکان — یک بار در روز بر اساس وزن: ۱۰ تا \u003C۲۰ kg: ۴۰ mg؛ ۲۰ تا \u003C۳۰: ۶۰؛ ۳۰ تا \u003C۴۵: ۷۰؛ ۴۵ به بالا: ۱۰۰ mg","Chronic-phase CML or Ph+ ALL, children — once daily by weight: 10–\u003C20 kg: 40 mg; 20–\u003C30: 60; 30–\u003C45: 70; ≥45: 100 mg",{"maxAge":111,"minWeightKg":112},{"value":76,"unit":77},10,"weightBand",{"weightBands":115},[116,120,123,125],{"minWeightKg":117,"maxWeightKg":118,"perDose":119,"dosesPerDay":5},9.99,19.99,40,{"minWeightKg":118,"maxWeightKg":121,"perDose":122,"dosesPerDay":5},29.99,60,{"minWeightKg":121,"maxWeightKg":124,"perDose":47,"dosesPerDay":5},44.99,{"minWeightKg":124,"maxWeightKg":126,"perDose":55,"dosesPerDay":5},150,[128],{"source":33,"section":129},"2.2, Table 1",[131],{"text":132,"refs":135},{"fa":133,"en":134},"هر ۳ ماه با وزن جدید محاسبه شود. زیر ۱۰ kg قرص توصیه نمی‌شود. قرص خرد یا جویده نشود.","Recalculate every 3 months by weight. Tablets not recommended under 10 kg. Do not crush or chew.",[136],{"source":33,"section":137},"2.2",[],[140],{"text":141,"refs":144},{"fa":142,"en":143},"سرکوب مغز استخوان؛ خونریزی؛ احتباس مایع (افیوژن پلور)؛ سمیت قلبی؛ فشار خون ریوی؛ طولانی شدن QT؛ واکنش پوستی شدید؛ لیز تومور؛ سمیت جنینی؛ اثر بر رشد کودکان؛ سمیت کبدی.","Myelosuppression; bleeding; fluid retention (pleural effusion); cardiac toxicity; pulmonary arterial hypertension; QT prolongation; severe skin reactions; tumour lysis; embryo-fetal toxicity; effects on growth in children; hepatotoxicity.",[145],{"source":33,"section":146},"5",[],[],[],{"status":151,"reviewer":152,"date":152},"unverified",null,[154,158,161,167],{"regimen":69,"formulation":52,"input":155,"expect":157},{"ageYears":156,"weightKg":47},55,{"perDose":55,"tabletsPerDoseRounded":5},{"regimen":91,"formulation":60,"input":159,"expect":160},{"ageYears":156,"weightKg":47},{"perDose":63,"tabletsPerDoseRounded":5},{"regimen":106,"formulation":22,"input":162,"expect":165},{"ageYears":163,"weightKg":164},6,15,{"perDose":119,"tabletsPerDoseRounded":166},2,{"regimen":106,"formulation":44,"input":168,"expect":171},{"ageYears":169,"weightKg":170},12,35,{"perDose":47,"tabletsPerDoseRounded":5},[173],"L01EA02",{"status":175,"forms":176,"refs":204},"registered",[177,181,185,189,193,197,201],{"code":178,"en":179,"fa":180},"16832","DASATINIB 20MG TAB","قرص داساتینیب ۲۰ میلی‌گرم",{"code":182,"en":183,"fa":184},"08613","DASATINIB 70MG TAB","قرص داساتینیب ۷۰ میلی‌گرم",{"code":186,"en":187,"fa":188},"52541","DASATINIB 140MG TAB","قرص داساتینیب ۱۴۰ میلی‌گرم",{"code":190,"en":191,"fa":192},"52539","DASATINIB 100MG TAB","قرص داساتینیب ۱۰۰ میلی‌گرم",{"code":194,"en":195,"fa":196},"50886","DASATINIB 50 MG TAB","قرص داساتینیب ۵۰ میلی‌گرم",{"code":198,"en":199,"fa":200},"52540","DASATINIB 80 mg TABLET","قرص داساتینیب ۸۰ میلی‌گرم",{"code":202,"en":203,"fa":180},"52542","DASATINIB TABLET ORAL 20 mg",[205],{"source":206,"section":207,"url":208},"darooyab-generic","G-4714\u002FDasatinib","https:\u002F\u002Fwww.darooyab.ir\u002FG-4714\u002FDasatinib",{"kind":210,"refs":211,"id":214},"NDA",[212],{"source":33,"section":213},"SPL approval \u002F marketing category","NDA021986",[216,219,223,226,229],{"kind":217,"url":218,"label":214},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021986",{"kind":220,"url":221,"label":222},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df","FDA Sprycel",{"kind":224,"url":225,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa607063.html",{"kind":227,"url":228,"label":173},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01EA02",{"kind":230,"url":208,"label":8},"darooyab",{"pregnancy":232,"lactation":241,"pediatric":249,"geriatric":258,"reproductive":266},{"level":233,"text":234,"quote":237,"refs":238},"avoid",{"fa":235,"en":236},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on limited human data, SPRYCEL can cause fetal harm when administered to a pregnant woman.",[239],{"source":33,"section":240},"8.1",{"level":233,"text":242,"quote":245,"refs":246},{"fa":243,"en":244},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in nursing children from SPRYCEL, breastfeeding is not recommended during treatment with SPRYCEL and for 2 weeks after the last dose.",[247],{"source":33,"section":248},"8.2",{"level":250,"text":251,"quote":254,"refs":255},"caution",{"fa":252,"en":253},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Ph+ CML in Chronic Phase The safety and effectiveness of SPRYCEL monotherapy have been demonstrated in pediatric patients with newly diagnosed chronic phase CML [see Clinical Studies (14.3) ] .",[256],{"source":33,"section":257},"8.4",{"level":250,"text":259,"quote":262,"refs":263},{"fa":260,"en":261},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","… ness, pericardial effusion, congestive heart failure, hypertension, pulmonary edema, and weight decrease, and should be monitored closely.",[264],{"source":33,"section":265},"8.5",{"level":250,"text":267,"quote":270,"refs":271},{"fa":268,"en":269},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with SPRYCEL and for 30 days after the last dose.",[272],{"source":33,"section":273},"8.3",1792444392069]